GR1008554B - Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου - Google Patents

Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου

Info

Publication number
GR1008554B
GR1008554B GR20140100334A GR20140100334A GR1008554B GR 1008554 B GR1008554 B GR 1008554B GR 20140100334 A GR20140100334 A GR 20140100334A GR 20140100334 A GR20140100334 A GR 20140100334A GR 1008554 B GR1008554 B GR 1008554B
Authority
GR
Greece
Prior art keywords
factor
preparation
antifugal
trizol
same
Prior art date
Application number
GR20140100334A
Other languages
English (en)
Inventor
Ευαγγελος Ανδρεα Καραβας
Original Assignee
ΦΑΡΜΑΤΕΝ ΑΝΩΝΥΜΟΣ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΙΑΤΡΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ με δ.τ. ΦΑΡΜΑΤΕΝ,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ΦΑΡΜΑΤΕΝ ΑΝΩΝΥΜΟΣ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΙΑΤΡΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ με δ.τ. ΦΑΡΜΑΤΕΝ, filed Critical ΦΑΡΜΑΤΕΝ ΑΝΩΝΥΜΟΣ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΙΑΤΡΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ με δ.τ. ΦΑΡΜΑΤΕΝ,
Priority to GR20140100334A priority Critical patent/GR1008554B/el
Priority to ES15730391T priority patent/ES2898456T3/es
Priority to US15/316,899 priority patent/US10328076B2/en
Priority to PCT/EP2015/001151 priority patent/WO2015188927A1/en
Priority to EP15730391.8A priority patent/EP3154525B1/en
Publication of GR1008554B publication Critical patent/GR1008554B/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893Tablet coating processes

Abstract

Η παρούσα εφεύρεση αφορά σταθερό φαρμακευτικό σκεύασμα στερεάς φαρμακοτεχνικής μορφής για χορήγηση διά στόματος το οποίο περιέχει θεραπευτικά δραστική ποσότητα ενός αντιμυκητιασικού παράγοντα τριαζόλης ή ενός φαρμακευτικά αποδεκτού άλατος αυτής, και συγκεκριμένα Βορικοναζόλη, καθώς και δραστική ποσότητα ενός παράγοντα ενίσχυσης της διαλυτότητας. Επίσης, η εφεύρεση αφορά και την μέθοδο παρασκευής του ως άνω σκευάσματος.
GR20140100334A 2014-06-12 2014-06-12 Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου GR1008554B (el)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GR20140100334A GR1008554B (el) 2014-06-12 2014-06-12 Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου
ES15730391T ES2898456T3 (es) 2014-06-12 2015-06-09 Composición farmacéutica que comprende un agente antifúngico triazol y método de preparación de la misma
US15/316,899 US10328076B2 (en) 2014-06-12 2015-06-09 Pharmaceutical composition comprising a triazole antifungal agent and method for preparation thereof
PCT/EP2015/001151 WO2015188927A1 (en) 2014-06-12 2015-06-09 Pharmaceutical composition comprising a triazole antifungal agent and method for preparation thereof
EP15730391.8A EP3154525B1 (en) 2014-06-12 2015-06-09 Pharmaceutical composition comprising a triazole antifungal agent and method for preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20140100334A GR1008554B (el) 2014-06-12 2014-06-12 Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου

Publications (1)

Publication Number Publication Date
GR1008554B true GR1008554B (el) 2015-09-03

Family

ID=53442713

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20140100334A GR1008554B (el) 2014-06-12 2014-06-12 Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου

Country Status (5)

Country Link
US (1) US10328076B2 (el)
EP (1) EP3154525B1 (el)
ES (1) ES2898456T3 (el)
GR (1) GR1008554B (el)
WO (1) WO2015188927A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112353769A (zh) * 2020-11-26 2021-02-12 珠海亿邦制药有限责任公司 一种粉末直压法制备伏立康唑片剂的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962522A (en) 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
JP2004002245A (ja) * 2002-06-03 2004-01-08 Towa Yakuhin Kk 溶出性を改善したイトラコナゾール経口投与製剤
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
DE602005010074D1 (de) 2004-05-28 2008-11-13 Pfizer Prod Inc Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
BRPI0721883A2 (pt) * 2007-07-23 2014-02-18 Pharmathen Sa Composição farmacêutica contendo antagonista de canal de cálcio de dihidropiridina e processo para a preparação da mesma
BRPI0905717A2 (pt) * 2008-01-11 2015-07-14 Cipla Ltd Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
US20110105448A1 (en) * 2008-06-06 2011-05-05 Glenmark Pharmaceuticals Limited Stable Topical Formulation Comprising Voriconazole
US20100086597A1 (en) 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst
RU2476206C1 (ru) * 2011-11-22 2013-02-27 Виктор Львович Лимонов Фармацевтическая композиция для приготовления инфузионных растворов антимикробных препаратов, способ ее получения (варианты)

Also Published As

Publication number Publication date
US20170095477A1 (en) 2017-04-06
WO2015188927A1 (en) 2015-12-17
EP3154525A1 (en) 2017-04-19
ES2898456T3 (es) 2022-03-07
US10328076B2 (en) 2019-06-25
EP3154525B1 (en) 2021-08-25

Similar Documents

Publication Publication Date Title
MX2020003825A (es) Formas de dosificacion solidas de palbociclib.
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
TW201613859A (en) Analogs of PRIDOPIDINE, their preparation and use
ZA201706227B (en) Vaporizer for vaporizing an active ingredient
SI3577110T1 (sl) 8-oksetan-3-IL-3,8-diazabiciklo(3.2.1)oktan-3-IL substituirane spojine kot zaviralci HIV-a
EP3373861A4 (en) IMPLANT SUPPLY CAPSULE
EP3302426A4 (en) D2o stabilized pharmaceutical formulations
UY36275A (es) Compuestos aminopirimidinilo
EP3367979A4 (en) Implant delivery capsule
CL2016003145A1 (es) Compuestos de [1,2,4]triazol sustituido
TW201613911A (en) Heterocyclic compounds and uses thereof
AU2020273281B2 (en) Therapeutic uses of ibogaine and related compounds
MX2015015562A (es) Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2.
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
MX2016015464A (es) Composicion farmaceutica oral de isotretinoina.
EP3125886A4 (en) Disubstituted triazole analogs
IN2014CH00840A (el)
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
MX2016015465A (es) Composicion farmaceutica oral de isotretinoina.
HK1232076A1 (zh) 用於取代的 -芐基- 異噁唑- -基甲基 -吡唑- -基 咪唑烷- -二酮的合成的改進方法
MY182634A (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
WO2016020408A3 (en) Compounds for preventing ototoxicity
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
EP3154524A4 (en) Extended-release drug delivery compositions

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20151022